RKDA
Arcadia Biosciences, Inc.
Next earnings Aug 12, 2026 · consensus $-0.57 EPS, $1.94M rev
Last earnings +0.9% on 2026-05-14
$0.69
▲ +2.16%$0.69▼ -83.54%
over 1Y
L $0.67EODHDH $5.48
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.2%
1W-10.6%
1M-25.4%
3M-53.1%
YTD-67.9%
1Y-83.5%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity 0.58x); but revenue declined -3.7% YoY.
Revenue (FY2025) $4.86M · FY2025
Arcadia Biosciences, Inc. shows $4.86M in FY2025 revenue (-3.7% YoY), a -48.1% net margin, and -56.5% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $6.78M | $7.42M | $4.45M | $5.04M | $4.86M |
| Gross profit | — | — | — | — | — |
| Operating income | -$35.5M | -$14.0M | -$6.10M | -$3.65M | -$2.50M |
| Net income | -$14.7M | -$15.4M | -$14.0M | -$7.04M | -$2.34M |
| Diluted EPS | -$27.56 | -$25.65 | -$11.29 | -$5.17 | -$1.71 |
| Net margin | -216.2% | -207.3% | -313.9% | -139.5% | -48.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.16M
EV / EBITDA—
EV / Sales0.2
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-164.9%
FCF yield-334.1%
Quality & risk
ROIC (est.)-47.7%
Free cash flow-$4.74M
Total debt$0.00
Net cash$259K
Altman Z-Score-59.52 distress
Piotroski F-Score3/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+50.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-04-30). Worth a closer look.
- S-3 Shelf registration (potential raise)2026-06-26
- 8-K Material agreement2026-06-15
- 8-K Earnings results2026-05-14
- 10-Q Quarterly report2026-05-14
- 10-K/A Restated periodic report2026-04-30
- 8-K Auditor change2026-04-03
- 8-K Earnings results2026-03-26
- 10-K Annual report2026-03-26
- 8-K Officer / director change2026-02-06
Recent filings
all on EDGAR ↗DFiling2026-06-26open ↗S-3Filing2026-06-26open ↗8-KPeriod ending 2026-06-112026-06-15open ↗SCHEDULE 13GFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-142026-05-14open ↗10-K/APeriod ending 2025-12-312026-04-30open ↗8-KPeriod ending 2026-03-302026-04-03open ↗10-KPeriod ending 2025-12-312026-03-26open ↗8-KPeriod ending 2026-03-262026-03-26open ↗424B3Filing2026-02-11open ↗EFFECTFiling2026-02-10open ↗
Frequently asked
- Is Arcadia Biosciences, Inc. (RKDA) a buy?
- RKDA currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.58x); but revenue declined -3.7% YoY.
- What is Arcadia Biosciences, Inc.'s quality score?
- RKDA scores 58.45098039215686/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001469443, latest 10-Q filed 2026-05-14) · EODHD · as of 6/26/2026, 1:22:03 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.